Please assess the completion status of the following clinical trial:

Trial Title: A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 but not older than 40 years of age at the time of screening~* Good physical and mental health~* Regular cycles with a usual length between 24 and 35 days~* Body mass index ≥ 18 and ≤ 29~* Willing to give informed consent in writing~Exclusion Criteria:~* Contraindications:~  * known or suspected pregnancy~ * active venous thromboembolic disorder (e.g. deep vein thrombosis,pulmonary embolism)~ * presence or history of severe hepatic disease as long as liver function values have not returned to normal~ * malignancy or pre-malignancy, if sex -steroid-influenced~ * undiagnosed vaginal bleeding~ * hypersensitivity to any of the components of Implanon/Radiopaque Implanon~* Hypertension, i.e. systolic blood pressure \>140 mmHg and/or diastolic blood pressure \> 90 mmHg.~* A history during pregnancy or during previous use of sex steroids of: jaundice and/or severe pruritus related to cholestasis; gallstone formation; porphyria; systemic lupus erythematosus; haemolytic uraemic syndrome; Sydenham's chorea; herpes gestationis; otosclerosis-related hearing loss~* Present use or use during 2 months prior to the start of Implanon/Radiopaque Implanon of one of the following drugs: phenytoin, phenobarbital, primidone, carbamazepine, rifampicin, oxcarbazepine, topiramate, felbamate, ritonavir, nelfinavir, griseofulvin or the herbal remedy St John's wort.~* Administration of investigational drugs within 2 months prior to the start of Implanon/Radiopaque Implanon

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Radiopaque Implanon (ro imp) (Type: ACTIVE_COMPARATOR): The radiopaque rod (Radiopaque Implanon) is similar to the Implanon rod except for the addition of barium sulfate.
- Implanon (imp) (Type: ACTIVE_COMPARATOR): Implanon® (Org 32222) is a single rod contraceptive implant of 4 cm length and~2 mm in diameter. Implanon® contains approximately 68 mg etonogestrel (ENG) (Org 3236, 3-ketodesogestrel) dispersed in a matrix of ethylene vinyl acetate (EVA)copolymer, surrounded by an EVA membrane.~The ENG dose released by Implanon® amounts to about 60-70 μg/day shortly after~insertion and decreases to about 40 μg/day at the start of the second year, and to about 25-30 μg/day at the end of the third year.

Based on this trial design, predict the completion outcome and termination type (if applicable).